Table 3A-1 Arthritis and gastrointestinal bleeding mortality codes | |
Disease Group |
ICD-9 Codes |
Connective Tissue Diseases |
446, 710 |
Rheumatoid Arthritis |
714 |
Osteoarthritis and Allied Disorders |
715 |
Other Arthritis |
098.5, 099.3, 274, 696, 711-713, 716-721 |
Rheumatism |
725-729 |
Arthritis and Related Conditions |
All of the above |
Gastrointestinal Bleeding |
531-531.6, 532-532.6 , 533-533.6, 534-534.6, 535.0, 578.0, 578.1, 578.9 |
Table 3A-2 Methods for calculating life expectancy and health-adjusted life expectancy (HALE) for people with arthritis |
Variable Definition |
The Health Utilities Index |
The Health Utilities Index (HUI3) was used to calculate health-adjusted life expectancy (HALE).28 The HUI3 is a utility-based, multi-attribute health classification system that estimates a summary value of individual health where 0.0 = “dead” and 1.0 = “perfect health” (states worse than death are also possible), based on preference scores for different health states.29 Each respondent in the CCHS 2000/01 answered questions pertaining to eight attributes of functional health: vision, hearing, speech, mobility, dexterity, emotional state, cognition and level of pain and discomfort. Each attribute has from 5 to 6 possible levels, ranging from unrestricted to a highly disabled state (see Torrance et al.30 for a description of health states). The eight attributes were then combined using preference scores from the HUI mark III version and the following multi-attribute utility function:31 u = 1.371 (u1 * u2 * u3 * u4 * u5 * u6 * u7 * u8) - 0.371 |
Analysis Methods |
Arthritis-deleted Mortality Rate and HUI3 Estimates |
Arthritis-deleted mortality rates and HUI3 estimates were calculated by subtracting the mortality rate for people with arthritis from the overall mortality rate for each age-sex group. Arthritis mortality for 1994-98 was used to reduce the variability of age-specific mortality rates. Arthritis-deleted HUI3 was calculated in a similar manner by removing all people with arthritis from the CCHS sample and recalculating the mean HUI3 for each age-sex group. |
Life Table Analysis |
Period life tables for 1996-98 for men and women were calculated using an adaptation of Chiang's method32 and 20 standard age groups (< 1,1-4, 5-9,…, 90+ years), except for an adaptation for the final age group.33 Arthritis-deleted life expectancy was calculated by substituting the arthritis-deleted mortality rates for the overall mortality rates in the life table.34 HALE was calculated using a modified Sullivan
method.35
Sullivan used a period life table and the prevalence of disability
to estimate the number of life years lived free of disability.
After calculation |
1. Callahan LF, Pincus T. Mortality in the rheumatic diseases. Arthritis Care Res 1995;8(4):229-41.
2. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37(4):481-94.
3. Doran MF, Pond GR, Crowson CS, O'Fallon WM, Gabriel SE. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum 2002;46(3):625-31.
4. Wong JB, Ramey DR,
Singh G. Long-term morbidity, mortality, and economics of
rheumatoid arthritis.
Arthritis Rheum 2001;44(12):2746-9.
5. Monson RR, Hall AP. Mortality among arthritics. J Chron Dis 1976;29:459-67.
6. Vandenbroucke JP, Hazevoet HM, Cats A. Survival and cause of death in rheumatoid arthritis: a 25-year prospective follow-up. J Rheumatol 1984;11(2):158-61.
7. Mutru O, Laakso M, Isomaki H, Koota K. Ten year mortality and causes of death in patients with rheumatoid arthritis. Br Med J (Clin Res Ed) 1985;290(6484):1797-9.
8. Myllykangas-Luosujarvi RA, Aho K, Isomaki HA. Mortality in rheumatoid arthritis. Sem Arthritis Rheum 1995;25(3):193-202.
9. Nurmohamed MT, van
Halm VP, Dijkmans BA. Cardiovascular risk profile of
antirheumatic agents in
patients with osteoarthritis and rheumatoid arthritis. Drugs
2002;62(11):1599-609.
10. Brandt KD. The role of analgesics in the management of osteoarthritis pain. Am J Ther 2000;7(2):75-90.
11. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2000;27(2):269-81.
12. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999;26(Suppl 56):18-24.
13. Goldstein JL. Who needs prophylaxis of nonsteroidal anti-inflammatory drug-induced ulcers and what is optimal prophylaxis? Eur J Gastroenterol Hepatol 2000;12(Suppl 1):S11-S15.
14. Wolfe MM,
Lichtenstein DR, Singh G. Gastrointestinal toxicity of
nonsteroidal anti-inflammatory drugs.
N Engl J Med 1999;340:984-91.
15. Singh G, Ramey DR, Morfeld D. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 1996;156:1530-6.
16. Bélanger A,
Martel L, Berthelot, JM., Wilkins R. Gender differences in
disability-free life expectancy for
selected risk factors and chronic conditions in Canada. J
Women Aging 2000;14(1/2):61-83.
17. Manuel DG, Schultz SE, Kopec JA. Measuring the health burden of chronic disease and injury using health adjusted life expectancy and the Health Utilities Index. J Epidemiol Community Health 2002;56:843-50.
18. Crimmins EM, Kim
JK, Hagedorn A. Life with and without disease: Women experience
more of both.
J Women Aging 2002;14(1/2):47-59.
19. Health Canada. Economic Burden of Illness in Canada, 1998. Ottawa: Public Works and Government Services Canada, 2002. (Catalogue # H21-136/1998E)
20. Wigle DT, Mao Y, Wong T, Lane R. Economic burden of illness in Canada, 1986. Chron Dis Can 1991;12(Suppl 3).
21. Moore R, Mao Y, Zhang J, Clarke K. Economic Burden of Illness in Canada, 1993. Ottawa: Canadian Public Health Association, 1997.
22. Vandenbroucke JP, Hazevoet HM, Cats A. Survival and cause of death in rheumatoid arthritis: a 25-year prospective follow up. J Rheumatol 1984;11(2):158-61.
23. Mutru O, Laakso M, Isomaki H, Koota K. Ten year mortality and causes of death in patients with rheumatoid arthritis. Br Med J (Clin Res Ed) 1985;290(6484):1797-9.
24. Myllykangas-Luosujarvi RA, Aho K, Isomaki HA. Mortality in rheumatoid arthritis. Sem Arthritis Rheum 1995;25(3):193-202.
25. Nurmohamed MT, van Halm VP, Dijkmans BA. Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis. Drugs 2002;62(11):1599-609.
26. Brandt KD. The role of analgesics in the management of osteoarthritis pain. Am J Ther 2000;7(2):75-90.
27. Coyte P, Asche C,
Croxford R, Chan B. The economic cost of arthritis and
rheumatism in Canada.
In: Williams JI, Badley EM, editors. Patterns of Health Care in
Ontario: Arthritis and Related Conditions. Toronto: Institute
for Clinical Evaluative Sciences, 1998; 11-26.
28. Feeny D, Torrance G, Furlong W. Health utilities index. In: Spilder B, editor. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven, 1996; chapter 26.
29. Feeny D, Furlong W, Boyle M, Torrance GW. Multi-attribute health status classification systems. Health Utilities Index. Pharmacoeconomics 1995;7(6):490-502.
30. Torrance G, Furlong W, Feeny D, Boyle M. Multi-attribute preference functions - Health Utilities Index. Pharmacoeconomics 1995;7(6):503-20.
31. Furlong W, Feeny D, Torrance G, Barr R. The Health Utilities Index (HUI) System for Assessing Health- Related Quality of Life in Clinical Studies. #01-02. 2001. Health Economics and Policy Analysis Research Working Paper.
32. Chiang CL. The Life Table and Its Applications. Malabar, Florida: Robert E. Krieger Publ. Co., 1984.
33. Hsieh J. A general theory of life table construction and a precise abridged life table method. Biomed J 1991;2:143-62.
34. Newman SC. Formulae for cause-deleted life tables. Stat Med 1987;6(4):527-8.
35. Sullivan DF. A single index of mortality and morbidity. HSMHA Health Reports 1971;86(4):347-54.
[Previous] [Table of Contents] [Next]